Research Into Benefits Of Prilactone®

A new publication into the benefits of spironolactone, the active ingredient in Prilactone® manufactured by CEVA Animal Health, has supported the use of the product as part of first-line therapy for the treatment of dogs with congestive heart failure caused by mitral heart disease. The double-blind placebo-controlled study1 involved 212 dogs on either spironolactone or a placebo, in addition to conventional therapy including an ACE inhibitor and furosemide. It revealed that over a 15 month period 25.5% of dogs either died, were euthanased or severely worsened in the placebo group compared to 10.8% in the spironolactone group. This represents a 55% reduction in the risk of cardiac morbidity-mortality and a 69% reduction in the risk of cardiac-related death or euthanasia. Further research2 has also revealed that aldosterone antagonists, such as spironolactone, help to prevent myocardial fibrosis, a pathogenic process involved in the progression of heart failure. Information is available by calling Fraser Broadfoot MRCVS at CEVA Animal Health on 01494 781510.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards